Abstract Number: 2231 • ACR Convergence 2022
Earlier and More Aggressive Treatment of Major Organ Involvement with Biologics May Prevent Relapses or Further New Organ Involvement in Behçet’s Disease
Background/Purpose: Behçet's disease (BD) is a chronic inflammatory disease affecting the eye, nervous system (CNS), vascular and gastrointestinal systems (GIS) as well as skin, mucosa,…Abstract Number: 1264 • ACR Convergence 2022
Does Vein Wall Thickness Have Prognostic Value in Behcet’s Disease? A Prospective Follow up Study
Background/Purpose: We reported the first controlled ultrasound study showing increased common femoral vein(CFV) thickness in Behçet's Disease(BD),1 and showed that this is a distinctive feature…Abstract Number: 1556 • ACR Convergence 2022
Distinct Clinical and Therapeutic Features Between Parenchymal and Non-parenchymal Manifestations in Neurobehçet’s Disease
Background/Purpose: Ocular and Neurobehçet's Disease (NBD) are the most severe manifestations of Behcet's disease. NBD can be classified as a) primary neural parenchymal lesions, also…Abstract Number: 1557 • ACR Convergence 2022
Microvascular Involvement in Behçet’s Disease: Study of Nailfold Capillaroscopy in Patients from a National Referral Center
Background/Purpose: Ocular and mucocutaneous manifestations of Behçet's disease (BD) are globally recognized and widely studied [Arthritis Rheumatol. 2019 Dec;71(12):2081-2089, Clin Exp Rheumatol. 2020 Sep-Oct;38 Suppl…Abstract Number: 1558 • ACR Convergence 2022
Prevalence, Phenotypical Clinical Clusters and Treatment of Neurobehçet’s Disease: Study in Northern Spain
Background/Purpose: Behçet's disease (BD) may present with different clinical phenotypes. Ocular and Neurobehçet's Disease (NBD) are severe complications. Data on NBD epidemiology, clinical phenotype and…Abstract Number: 1559 • ACR Convergence 2022
Long Term Clinical Effects of Apremilast on Behcet’s Disease and Changes in Serum Cytokines
Background/Purpose: Apremilast, the small-molecule phosphodiesterase -4 inhibitor, was approved for the treatment of recurrent oral ulcers associated with Behcet's disease (BD) in Japan from September…Abstract Number: 1560 • ACR Convergence 2022
Modulation of NKG2D Expression on NK, NKT and CD8+ T Lymphocytes by in Vitro Treatments of Immune Cells from Patients with Behçet Disease
Background/Purpose: Behçet disease (BD) is an inflammatory chronic disease characterized by alternation of active and inactive phases. Steroids, Colchine, Azathioprine (Aza) and interferon α are…Abstract Number: 1561 • ACR Convergence 2022
Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement
Background/Purpose: A considerable number of patients with Behçet's syndrome (BS) have vitreous cells on slit lamp examination at the time of diagnosis. However, the prognostic…Abstract Number: 1562 • ACR Convergence 2022
Validation of Behçet’s Disease Overall Damage Index (BODI) for Retrospective Studies and a Proposal for Modification
Background/Purpose: Damage accrual in Behçet syndrome (BS) may progress over the years and an index that can be scored using retrospective data may be useful…Abstract Number: 1881 • ACR Convergence 2021
Surgical Outcomes After Operative Procedures in Patients with Behcet’s Disease
Background/Purpose: Behcet's disease (BD) is characterized by hyper-inflammatory response to trauma, which is called the pathergy phenomenon. Therefore, there are concerns about post-operative complications when…Abstract Number: 1883 • ACR Convergence 2021
Neuro-Behcet’s Disease: 20 Years Single Center Experience of Cyclophosphamide for Induction of Remission
Background/Purpose: Behçet's disease (BD) is a systemic vasculitis. Neurological involvement, also known as Neuro-Behçet's disease (NBD), leads to great morbimortality. Diagnosis is challenging, since clinical…Abstract Number: 1885 • ACR Convergence 2021
Biological Therapy in Refractory Neurobehçet’s Disease. Multicenter Study of 42 Patients
Background/Purpose: Neurobehçet’s disease (NBD) is a severe complication of Behcet's disease (BD). Despite well-established therapies, with glucocorticoids and conventional immunosuppressants (cIS) a significant proportion of…Abstract Number: 1887 • ACR Convergence 2021
Evidence-Based Behçet’s Disease Activity Scale (EBDA) – A New Instrument with Improved Acuity for Major Organ Disease Activity and Remission Depth Assessment
Background/Purpose: Most current Behçet’s disease (BD) activity assessment tools are strongly based on patient-reported symptoms and findings allowing a wide range of observer-dependent interpretations and…Abstract Number: 1046 • ACR Convergence 2021
Risk of Ocular Comorbidities and Blindness Among Patients with Behçet’s Disease: A Nationwide Population-based Cohort Study in Korea
Background/Purpose: To examine the risk of ocular comorbidities in a nation-wide cohort of patients with Behçet’s disease (BD) compared to general population in Korea.Methods: We…Abstract Number: 1050 • ACR Convergence 2021
Epidemiology and Clinical Features of Ophthalmological Manifestations in Behçet’s Disease: Study of 50 Patients of a Series of 120 Patients in a Region in Northern Spain
Background/Purpose: Ophthalmological involvement is one of the most feared manifestations of Behçet’s disease.The aim of this study was to define the main demographic and clinical…
ACR Meeting Abstracts